Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects
Atrial Fibrillation, Atrial Flutter
About this trial
This is an interventional treatment trial for Atrial Fibrillation focused on measuring Atrial fibrillation, atrial flutter, anti-arrhythmic agents, conversion to normal sinus rhythm
Eligibility Criteria
Inclusion Criteria: Willing to sign informed consent before screening examinations are performed and before the study drug is administered Females > 18 years of age Subjects with documented (60 second rhythm strip) symptomatic atrial fibrillation or flutter (duration > 3 hours and < 45 days) at the time of randomization Subjects who are in no distress and hemodynamically stable (supine systolic blood pressure > 90 mmHg and diastolic blood pressure < 105 mmHg) Exclusion Criteria: Pregnancy and lactation Acute myocardial infarction and cerebrovascular accidents Coronary syndromes and congestive heart failure (CHF) New York Heart Association (NYHA) IV Life-threatening ventricular arrhythmias and electrocardiogram (ECG) abnormalities Concurrent antiarrhythmic treatments
Sites / Locations
- Site 82
- Site 2
- Site 3
- Site 5
- Site 4
- Site 8
- Site 11
- Site 9
- Site 10
- Site 14
- Site 6
- Site 7
- Site 12
- Site 13
- Site 52
- Site 53
- Site 54
- Site 57
- Site 58
- Site 56
- Site 55
- Site 15
- Site 17
- Site 16
- Site 18
- Site 19
- Site 22
- Site 23
- Site 20
- Site 21
- Site 26
- Site 32
- Site 30
- Site 29
- Site 36
- Site 31
- Site 33
- Site 24
- Site 25
- Site 27
- Site 28
- Site 34
- Site 35
- Site 38
- Site 39
- Site 40
- Site 37
- Site 41
- Site 42
- Site 43
- Site 44
- Site 45
- Site 46
- Site 47
- Site 48
- Site 49
- Site 51
- Site 50
- Site 60
- Site 64
- Site 61
- Site 62
- Site 59
- Site 65
- Site 63
- Site 66
- Site 67
- Site 68
- Site 69
- Site 71
- Site 72
- Site 75
- Site 70
- Site 73
- Site 76
- Site 77
- Site 74
- Site 80
- Site 79
- Site 78
- Site 81